Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Co-Diagnostics, Inc. CODX
$1.37
+$0.14 (10.48%)
На 18:01, 12 мая 2023
+337.96%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
38344024.00000000
-
week52high
7.13
-
week52low
1.20
-
Revenue
34218209
-
P/E TTM
-3
-
Beta
-0.61799300
-
EPS
-0.44000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| Sidoti & Co. | Neutral | Buy | 12 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 ноя 2021 г. |
| Maxim Group | Hold | Buy | 29 мар 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Egan Dwight H | A | 471667 | 155000 | 17 янв 2023 г. |
| Brown Brian Lee | A | 377500 | 130000 | 17 янв 2023 г. |
| MURPHY TED | A | 98333 | 40000 | 17 янв 2023 г. |
| SERBIN RICHARD S | A | 98333 | 40000 | 17 янв 2023 г. |
| NELSON JAMES B | A | 98333 | 40000 | 17 янв 2023 г. |
| Durenard Eugene | A | 98333 | 40000 | 17 янв 2023 г. |
| MURPHY TED | D | 58333 | 12500 | 08 янв 2023 г. |
| MURPHY TED | A | 49167 | 12500 | 08 янв 2023 г. |
| SERBIN RICHARD S | D | 58333 | 12500 | 08 янв 2023 г. |
| SERBIN RICHARD S | A | 39167 | 12500 | 08 янв 2023 г. |
Новостная лента
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 22:33
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon and welcome to the Co-Diagnostics' First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded today.
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.26 per share a year ago.
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
16 мар 2023 г. в 19:05
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 18:37
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call.
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
PRNewsWire
09 мар 2023 г. в 09:30
SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.